Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 218

1.

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K.

Drug Des Devel Ther. 2014 Aug 25;8:1151-9. doi: 10.2147/DDDT.S66812. eCollection 2014.

PMID:
25187697
[PubMed - in process]
Free PMC Article
2.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K.

Oncoimmunology. 2014 May 14;3:e28861. eCollection 2014.

PMID:
25057448
[PubMed]
Free PMC Article
3.

Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines.

Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH.

Biochem Pharmacol. 2014 Jun 1;89(3):361-9. doi: 10.1016/j.bcp.2014.03.008. Epub 2014 Mar 26.

PMID:
24680865
[PubMed - indexed for MEDLINE]
4.

Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.

Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH.

J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.

PMID:
24133215
[PubMed - indexed for MEDLINE]
5.

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K.

Cancer Sci. 2013 Sep;104(9):1146-53. doi: 10.1111/cas.12216. Epub 2013 Jul 9.

PMID:
23758044
[PubMed - indexed for MEDLINE]
6.

Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease.

Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T, Setoguchi Y, Ohyashiki K.

Int J Mol Med. 2013 Mar;31(3):533-9. doi: 10.3892/ijmm.2013.1251. Epub 2013 Jan 21.

PMID:
23338559
[PubMed - indexed for MEDLINE]
7.

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.

Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K.

Br J Haematol. 2013 Jan;160(2):269-71. doi: 10.1111/bjh.12111. Epub 2012 Nov 1. No abstract available.

PMID:
23116058
[PubMed - indexed for MEDLINE]
8.

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K.

Blood Cancer J. 2012 Jan;2(1):e53. doi: 10.1038/bcj.2011.51. Epub 2012 Jan 20.

PMID:
22829237
[PubMed]
Free PMC Article
9.

Leukemia cell to endothelial cell communication via exosomal miRNAs.

Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH.

Oncogene. 2013 May 30;32(22):2747-55. doi: 10.1038/onc.2012.295. Epub 2012 Jul 16.

PMID:
22797057
[PubMed - indexed for MEDLINE]
10.

Telomere length shortening in patients with dementia with Lewy bodies.

Kume K, Kikukawa M, Hanyu H, Takata Y, Umahara T, Sakurai H, Kanetaka H, Ohyashiki K, Ohyashiki JH, Iwamoto T.

Eur J Neurol. 2012 Jun;19(6):905-10. doi: 10.1111/j.1468-1331.2011.03655.x. Epub 2012 Jan 31.

PMID:
22288427
[PubMed - indexed for MEDLINE]
11.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

PMID:
22251709
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes.

Ohyashiki M, Ohyashiki JH, Hirota A, Kobayashi C, Ohyashiki K.

Immun Ageing. 2011 Nov 15;8(1):11. doi: 10.1186/1742-4933-8-11.

PMID:
22082184
[PubMed]
Free PMC Article
13.

Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.

Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T.

Br J Haematol. 2012 Apr;157(2):254-6. doi: 10.1111/j.1365-2141.2011.08939.x. Epub 2011 Nov 11. No abstract available.

PMID:
22077498
[PubMed - indexed for MEDLINE]
14.

Association between ApoE phenotypes and telomere erosion in Alzheimer's disease.

Takata Y, Kikukawa M, Hanyu H, Koyama S, Shimizu S, Umahara T, Sakurai H, Iwamoto T, Ohyashiki K, Ohyashiki JH.

J Gerontol A Biol Sci Med Sci. 2012 Apr;67(4):330-5. doi: 10.1093/gerona/glr185. Epub 2011 Oct 19.

PMID:
22016362
[PubMed - indexed for MEDLINE]
15.

Non-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemia.

Kitahara T, Umezu T, Ando K, Kodama A, Ohyashiki JH, Ohyashiki K.

Hematology. 2011 May;16(3):139-42. doi: 10.1179/102453311X12953015767338.

PMID:
21669052
[PubMed - indexed for MEDLINE]
16.

Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy.

Umezu T, Ohyashiki K, Ohyashiki JH.

Anal Biochem. 2011 Aug 15;415(2):145-50. doi: 10.1016/j.ab.2011.04.035. Epub 2011 Apr 27.

PMID:
21600184
[PubMed - indexed for MEDLINE]
17.

Poloxamer 188 enhances apoptosis in a human leukemia cell line.

Aoki N, Tamura M, Ohyashiki JH, Sugaya M, Hisatomi H.

Mol Med Rep. 2010 Jul-Aug;3(4):669-72. doi: 10.3892/mmr_00000314.

PMID:
21472296
[PubMed]
18.

Cytogenetics in myelodysplastic syndromes.

Ohyashiki K, Kodama A, Ohyashiki JH.

Methods Mol Biol. 2011;730:79-88. doi: 10.1007/978-1-61779-074-4_6.

PMID:
21431635
[PubMed - indexed for MEDLINE]
19.

Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.

Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, Tanaka M, Kuroda M, Ohyashiki JH.

PLoS One. 2011 Feb 24;6(2):e16408. doi: 10.1371/journal.pone.0016408.

PMID:
21383985
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.

Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K.

BMC Res Notes. 2010 Dec 24;3:347. doi: 10.1186/1756-0500-3-347.

PMID:
21182798
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk